Identification, Ki determination and CoMFA analysis of nuclear receptor ligands as competitive inhibitors of OATP1B1-mediated estradiol-17β-glucuronide transport
Introduction
Severe adverse drug–drug interactions represent an increasing risk for patients taking several drugs at the same time. There is convincing evidence that besides at the level of drug metabolizing enzymes, drug–drug interactions also occur at the level of drug transporters. The human liver is the major organ for the uptake, metabolism and excretion of numerous drugs and other xenobiotics. The first step in hepatic clearance of such chemicals is the uptake of these substances from blood into liver mediated by transporters located on the basolateral membrane of hepatocytes. Organic anion transporting polypeptides (humans: OATPs; rodents: Oatps) are a group of membrane solute carriers that mediate the sodium-independent transport of a wide range of amphipathic organic compounds including numerous drugs and other xenobiotics [1], [2], [3]. So far, 11 human OATPs have been identified [2], [3]. The polyspecific OATP1B1 is exclusively expressed at the basolateral membrane of hepatocytes [4], [5], [6], [7] and is important for drug uptake.
Nuclear receptors are important ligand-activated transcription factors that strongly affect xenobiotic disposition. Furthermore, they are important drug targets for human diseases like diabetes, obesity and cancer [8], [9], [10], [11]. Nuclear receptors play important roles in the regulation of gene expression for metabolism, conjugation and transport of endogenous and exogenous compounds [12], [13], [14]. To exert their physiological effects, the ligands of nuclear receptors need to enter their target cells and transport proteins play a role during this process. For instance, the pregnane X receptor (PXR) ligand rifampicin [15], [16] and the farnesoid X receptor (FXR) ligand cholic acid [17], [18] are transported by OATP1B1 and 1B3; the thyroid hormones triiodothyronine (T3) and l-thyroxine (T4) are transported by OATP1 and OATP4 family members [4], [19], [20], [21], [22], [23]. Besides being transported directly, interactions of nuclear receptor ligands with transporters could result in unexpected potentially adverse effects. Previous studies showed that the peroxisome proliferator-activated receptor (PPAR) ligand troglitazone caused intracellular accumulation of bile salts and subsequent liver damage due to its inhibition of the canalicular bile salt export pump (BSEP) [24], and that the glucocorticoid receptor ligand dexamethasone inhibited OATP1A2-mediated dehydroepiandrosterone sulfate transport [25]. We recently demonstrated that the PXR ligand clotrimazole inhibited OATP1B1-mediated estradiol-17β-glucuronide transport, but stimulated OATP1B3-mediated estradiol-17β-glucuronide transport [26].
Given that adverse drug–drug interactions can be a result of inhibition at the uptake transporter level, there is a critical need to understand the polyspecificity of OATP1B1 to predict and prevent such adverse effects. Due to the difficulty of isolating and crystallizing membrane proteins, researchers attempted to elucidate the characteristics of the substrate binding sites of OATPs/Oatps based on the information of interacting small molecules. Chang et al. [27] used computational pharmacophore modeling to illuminate the key features for substrate interaction with rat Oatp1a1 and human OATP1B1 transporters. Yarim et al. [28] applied a three-dimensional quantitative structure–activity relationship (3D-QSAR) technique to obtain structural information of the substrate binding site of Oatp1a5. In these studies, the substrates used to derive theoretical models might bind to different sites as experimental evidence shows that OATPs/Oatps [26], [29], [30] as well as other transporters [31], [32] might have multiple substrate/ligand recognition sites. A computational model derived from compounds binding at the same site should be more reasonable and reliable. Therefore we decided to use competitive inhibitors of the OATP1B1 model substrate estradiol-17β-glucuronide which bind to the same site as the substrate to derive a model. From about 40 nuclear receptor ligands we identified inhibitors of OATP1B1-mediated transport, carried out kinetic studies to identify the competitive inhibitors and calculated their Ki values. Finally, we performed comparative molecular field analysis (CoMFA) on the identified competitive inhibitors to elucidate possible binding mechanism between OATP1B1 and its ligands.
Section snippets
Chemicals and reagents
Radiolabeled [3H]estradiol-17β-glucuronide (39.8 Ci/mmol) was purchased from PerkinElmer Life Sciences (Boston, MA). Nuclear receptor ligands were obtained from Sigma–Aldrich (St. Louis, MO) and Steraloids Inc. (Newport, RI). Cell culture reagents were from Invitrogen (Carlsbad, CA), fetal bovine serum from Hyclone (Logan, UT). The BCA protein assay kit was from Pierce (Rockford, IL).
Cell culture and uptake experiments
The Chinese Hamster Ovary (CHO) stable cell line expressing human OATP1B1 was described previously [26].
Identification of inhibitors of the model substrate estradiol-17β-glucuronide for OATP1B1
Estradiol-17β-glucuronide is one of the typical and well characterized OATP1B1 substrates which are amphipathic organic compounds containing hydrophobic and negatively charged groups. To identify potential inhibitors of estradiol-17β-glucuronide, inhibition experiments were performed for 39 compounds including 37 nuclear receptor ligands, the HMG-CoA reductase inhibitor pravastatin and the anti-fungal agent fluconazole (Fig. 1). As shown in Fig. 1, estradiol-17β-glucuronide was strongly
Conclusion
In the present study, we determined the Ki values for 21 competitive inhibitors of the model substrate estradiol-17β-glucuronide for OATP1B1 ranging from submicromolar to submillimolar. Most of these compounds are nuclear receptor ligands and contain a hydrophobic center and a negatively charged center. CoMFA analysis was carried out on the substrate and competitive inhibitors to explore the structural requirement for inhibitors that interact with OATP1B1 at the same site as the model substrate
Acknowledgment
This work was supported by National Institute of Health grants RR021940, GM077336 and the KUMC Biomedical Research Training Program 2007–2008.
References (36)
- et al.
Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties
Pflugers Arch
(2004) - et al.
The superfamily of organic anion transporting polypeptides
Biochim Biophys Acta
(2003) - et al.
Pharmacogenomics of human OATP transporters
Naunyn Schmiedebergs Arch Pharmacol
(2006) - et al.
Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1
J Biol Chem
(1999) - et al.
LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers
Gastroenterology
(2001) - et al.
A novel human hepatic organic anion transporting polypeptide (OATP2) Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters
J Biol Chem
(1999) - et al.
A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane
Am J Physiol
(2000) - et al.
The nuclear receptor superfamily
J Cell Sci
(2003) Orphan nuclear receptors: from gene to function
Endocrin Rev
(1999)- et al.
Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes
Clin Pharmacokinet
(2003)
Orphan nuclear receptor-mediated xenobiotic regulation in drug metabolism
Drug Discov Today
Nuclear receptors and lipid physiology: opening the X-files
Science
Drug-activated nuclear receptors CAR and PXR
Ann Med
Regulation of transporters by nuclear hormone receptors: implications during inflammation
Mol Pharm
Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver
Hepatology
Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation
J Pharmacol Exp Ther
Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6
J Biol Chem
OATP8/1B3-mediated cotransport of bile acids and glutathione: an export pathway for organic anions from hepatocytes?
J Biol Chem
Cited by (37)
Novel inhibitors of breast cancer resistance protein (BCRP, ABCG2) among marketed drugs
2023, European Journal of Pharmaceutical SciencesEnvironmental contaminants modulate transport activity of zebrafish organic anion transporters Oat1 and Oat3
2020, Comparative Biochemistry and Physiology Part - C: Toxicology and PharmacologyInvestigation of the interactions between flavonoids and human organic anion transporting polypeptide 1B1 using fluorescent substrate and 3D-QSAR analysis
2020, Biochimica et Biophysica Acta - BiomembranesCitation Excerpt :These results also indicated that the number of hydroxyl groups on ring B should not exceed two for flavonoids to have a strong inhibitory potency. Previously, we proposed an interaction model between OATP1B1 and nuclear receptor ligands, in which a negative charge center and a hydrophobic center of the ligands were important for their binding [38]. Flavonoids do not have an explicit negative charge center.
Individual serum bile acid profiling in rats aids in human risk assessment of drug-induced liver injury due to BSEP inhibition
2018, Toxicology and Applied PharmacologyCitation Excerpt :However, a dose-dependence in incidence of red urine was observed that ranged from 15% in controls to 75% at 50 mg/kg, suggesting that troglitazone contributes to the hemolytic profile (data not shown). Increases in total bilirubin could be due to: 1) a direct effect of the vehicle and/or troglitazone on erythrocyte lysis or 2) due to inhibition of uptake transporters such as OATPs (Gui et al., 2009); or 3) a combination of both factors. However, these total bilirubin changes are not likely due to cholestatic injury caused by apical membrane transporter inhibition as no meaningful effects on direct (conjugated) bilirubin were observed.
Molecular properties associated with transporter-mediated drug disposition
2017, Advanced Drug Delivery ReviewsCitation Excerpt :With the quality and size of the datasets limited to some extent, the current pharmacophore models broadly suggest molecular weight (MW), ionization state, hydrogen bonding ability, and lipophilicity are important determinants for substrate affinity to OATP1B1 [41]. A comparative molecular field analysis model (CoMFA) shows that OATP1B1 substrates binding sites consist of a large hydrophobic region with basic residues at both ends [42]. A pharmacophore containing two HBAs, one HBD, and two hydrophobic regions build through 3D-QSAR studies of OATP substrates showed promise [40].